We are live on
!
Find out more
ICM
ISZO Capital Management Portfolio holdings
AUM
$2M
1-Year Est. Return
35.61%
This Fund
S&P 500
This Quarter
Est. Return
-14.27%
1 Year Est. Return
+35.61%
3 Year Est. Return
+68.24%
5 Year Est. Return
+471.73%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$48.7M
(-18%)
Cap. Flow
-$13.2M
Cap. Flow
% of AUM
-5.82%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
3
Increased
2
Reduced
–
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lifecore Biomedical
LFCR
|
+$17.9M |
| 2 |
NTP
Nam Tai Property Inc.
NTP
|
+$17.9M |
| 3 |
Cryo-Cell International
CCEL
|
+$6.12M |
| 4 |
NOTV
Inotiv
NOTV
|
+$1.67M |
| 5 |
MTBL
Moatable, Inc. American Depositary Share (each representing forty-five (45) Class A Ordinary Shares)
MTBL
|
+$405K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DMTK
DermTech, Inc. Common Stock
DMTK
|
+$45.3M |
| 2 |
Anterix
ATEX
|
+$7.58M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$4.21M |
| 4 |
CHS
Chicos FAS, Inc.
CHS
|
+$136K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 60.43% |
| 2 | Healthcare | 35.87% |
| 3 | Consumer Discretionary | 3.48% |
| 4 | Technology | 0.22% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NTP
1
DELISTED
Nam Tai Property Inc.
NTP
| $137M | 60.43% |
5,891,377
+761,787
| +15% | +$17.9M |
|
|
CDMO
2
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $50.6M | 22.33% |
2,346,961
| – | – |
|
|
3
Lifecore Biomedical
LFCR
$166M
| $15.2M | 6.71% |
+1,648,520
| New | +$17.9M |
|
|
NOTV
4
DELISTED
Inotiv
NOTV
| $9.48M | 4.18% |
324,129
+57,249
| +21% | +$1.67M |
|
5
XPEL
XPEL
$1.22B
| $7.88M | 3.48% |
103,860
| – | – |
|
|
6
Cryo-Cell International
CCEL
$27.6M
| $6.01M | 2.65% |
+496,503
| New | +$6.12M |
|
|
MTBL
7
DELISTED
Moatable, Inc. American Depositary Share (each representing forty-five (45) Class A Ordinary Shares)
MTBL
| $506K | 0.22% |
+363,840
| New | +$405K |
|
|
8
Anterix
ATEX
$1.81B
| – | – |
-126,311
| Closed | -$7.58M |
|
|
9
Protagonist Therapeutics
PTGX
$8.79B
| – | – |
-93,883
| Closed | -$4.21M |
|
|
DMTK
10
DELISTED
DermTech, Inc. Common Stock
DMTK
| – | – |
-1,090,254
| Closed | -$45.3M |
|
|
CHS
11
DELISTED
Chicos FAS, Inc.
CHS
| – | – |
-20,690
| Closed | -$136K |
|
Similar funds
LBC
TA
SCM
LCMP
GIP
STC
GC
DU
ISZO Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, ISZO Capital Management held 11 positions worth $227M, down 18% from $275M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
ISZO Capital Management withdrew a net $13.2M in Q3 2021, closing 4 positions. Its most notable exit was DermTech, Inc. Common Stock, an estimated $45.3M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 52% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, ISZO Capital Management opened a new position in Lifecore Biomedical worth $15.2M.
- ISZO Capital Management's largest Q3 2021 buy was Lifecore Biomedical: 1,648,520 shares worth $15.2M.
- ISZO Capital Management added most to Nam Tai Property Inc. in Q3 2021, an estimated $17.9M increase.
- ISZO Capital Management fully exited DermTech, Inc. Common Stock in Q3 2021, selling an estimated $45.3M.
- ISZO Capital Management's ten largest holdings make up 100% of its $227M portfolio in Q3 2021.
- ISZO Capital Management opened 3 new positions and closed 4 in Q3 2021.
- ISZO Capital Management's portfolio value fell 18% quarter-over-quarter to $227M.
Based on ISZO Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.